<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The variable domain of immunoglobulin heavy chain (Ig HV) is well-characterized <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> associated antigen expressed in B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, which may function as a T-cell target </plain></SENT>
<SENT sid="1" pm="."><plain>However, T-cell <z:chebi fb="0" ids="53000">epitopes</z:chebi> derived from shared framework regions (FRs) of each IgHV subfamily capable of inducing cytotoxic T lymphocytes (CTLs) against the B-cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, have not been identified </plain></SENT>
<SENT sid="2" pm="."><plain>Using the specific PCR primers of seven IgHV gene subfamilies, we amplified the IgHV gene rearrangement for 108 cases of B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) patients </plain></SENT>
<SENT sid="3" pm="."><plain>The IgHV gene rearrangement fragments of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients were directly sequenced then classified into seven different subfamilies </plain></SENT>
<SENT sid="4" pm="."><plain>The T-cell <z:chebi fb="0" ids="53000">epitopes</z:chebi> encoded by the IgHV gene in the <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> patients were predicted by SYFPEITHI and BIMAS programs and compared with those from 56 representative germline IgHV sequences in the genebank </plain></SENT>
<SENT sid="5" pm="."><plain>For the HLA-A*0201 locus, we found 1 or 2 top score shared <z:chebi fb="0" ids="53000">epitopes</z:chebi> from each subfamily and got 12 epitopes altogether </plain></SENT>
<SENT sid="6" pm="."><plain>Results showed that ten of them were in the FRs </plain></SENT>
<SENT sid="7" pm="."><plain>Using an antigen-specific T-cell expansion system, we generated the <z:chebi fb="7" ids="16670">peptide</z:chebi>-special CTLs in vitro, which were capable of killing B <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines that belonged to the same IgHV subfamily in a <z:chebi fb="7" ids="16670">peptide</z:chebi>-specific and HLA-restricted manner </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, we proved that the cytotoxicity of CTLs was IgHV subfamily-specific </plain></SENT>
<SENT sid="9" pm="."><plain>These data indicate possible immunotherapy approaches for B-cell malignances patients based on IgHV gene subfamilies </plain></SENT>
</text></document>